Lucinda McDade of Claremont University Graduate honored by the American Horticultural Society – Daily Bulletin

Lucinda McDade, Executive Director and Judith B. Friend Director of Research at the California Botanic Garden, was named the 2021 recipient of the American Horticultural Society’s Liberty Hyde Bailey Award, the organization’s highest honor. The award is presented to an individual who has made a significant contribution during their lifetime …

Read More »

Diploma program for laboratory professionals

Shanghai Jiao Tong University School of Medicine has launched a five-year master’s program for medical students majoring in laboratory medicine. Students must complete a four-year course in Shanghai and a fifth year in France. The program involves training laboratory medicine professionals to meet a growing demand for clinical and scientific …

Read More »

Intensity Therapeutics Announces Presentation of Two Abstracts at American Society of Clinical Oncology (ASCO) Annual Meeting 2021

Intensity Therapeutics, Inc. (“Intensity”), a clinical-stage biotechnology company developing proprietary intratumoral products to kill tumors and increase recognition of cancers by the immune system, today announced two poster presentations at the occasion of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8. Title: …

Read More »

Study confirms effectiveness of uveitis treatment

Reviewed by Bahram Bodaghi, MD, PhD The results of LOUVRE 2, a French post-marketing, prospective and observational study, confirm the real effectiveness of the intravitreal implant of dexamethasone 0.7 mg (Ozurdex, Allergan) for the treatment of non-infectious uveitis of the posterior segment relatively long-standing. The results also provide insight into …

Read More »

Oncopeptides Announces Three Abstracts Accepted By American Society of Clinical Oncology 2021

WALTHAM, Massachusetts, May 19, 2021 / PRNewswire / – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotechnology company focused on developing therapies for difficult-to-treat hematologic diseases, today announces that three abstracts containing data on PEPAXTO® (melphalan flufenamide, also known as melflufen) in relapsed refractory multiple myeloma, have been accepted …

Read More »

Voyager Therapeutics (VYGR) Announces Strategic Change and Leadership Transitions

Enter Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases, today announced key leadership transitions and a strategic shift towards a refocused pipeline and increased investment in its innovative, …

Read More »